Viatris Valuation
Is VTRS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of VTRS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: VTRS ($9.87) wird unter unserer Schätzung des Fair Value ($42.66) gehandelt.
Deutlich unter dem Marktwert: VTRS wird um mehr als 20 % unter dem Marktwert gehandelt.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VTRS?
Other financial metrics that can be useful for relative valuation.
| What is VTRS's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$13.97b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 6.4x |
| PEG Ratio | 16x |
Price to Sales Ratio vs Peers
How does VTRS's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.7x | ||
TEVA Teva Pharmaceutical Industries | 1x | 2.2% | US$15.6b |
RPRX Royalty Pharma | 5.5x | 7.4% | US$17.2b |
CTLT Catalent | 2.5x | 7.4% | US$10.3b |
ELAN Elanco Animal Health | 1.7x | 3.5% | US$7.6b |
VTRS Viatris | 0.9x | -1.2% | US$14.0b |
Price-To-Sales gegen Gleichaltrige: VTRS ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (6.5x) mit dem Durchschnitt der anderen Unternehmen (50.5x) vergleicht.
Price to Earnings Ratio vs Industry
How does VTRS's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales gegen Industrie: VTRS ist aufgrund seines Price-To-Earnings Verhältnisses (6.5x) im Vergleich zum US Pharmaceuticals Branchendurchschnitt (26.7x) ein guter Wert.
Price to Sales Ratio vs Fair Ratio
What is VTRS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.9x |
| Fair PS Ratio | 3.9x |
PM vs. Fair Ratio: VTRS ist ein guter Wert auf der Grundlage des Verhältnisses Price-To-Earnings (6.5x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (18.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$11.80 | US$12.40 +5.0% | 7.0% | US$14.00 | US$11.00 | n/a | 9 |
| Mar ’25 | US$12.59 | US$11.95 -5.1% | 9.6% | US$14.00 | US$10.00 | n/a | 9 |
| Feb ’25 | US$11.87 | US$11.73 -1.2% | 11.1% | US$14.00 | US$10.00 | n/a | 9 |
| Jan ’25 | US$10.83 | US$11.62 +7.3% | 12.7% | US$14.00 | US$9.00 | n/a | 9 |
| Dec ’24 | US$9.37 | US$11.61 +23.9% | 13.5% | US$14.00 | US$9.00 | n/a | 8 |
| Nov ’24 | US$8.92 | US$11.74 +31.6% | 13.9% | US$14.00 | US$9.00 | n/a | 8 |
| Oct ’24 | US$9.86 | US$12.66 +28.4% | 11.2% | US$15.00 | US$10.00 | n/a | 9 |
| Sep ’24 | US$10.79 | US$12.46 +15.4% | 12.0% | US$15.00 | US$10.00 | n/a | 9 |
| Aug ’24 | US$10.22 | US$12.34 +20.8% | 12.0% | US$15.00 | US$10.00 | n/a | 9 |
| Jul ’24 | US$9.98 | US$12.51 +25.4% | 11.9% | US$15.00 | US$10.00 | n/a | 10 |
| Jun ’24 | US$9.18 | US$12.66 +37.9% | 11.8% | US$15.00 | US$10.00 | n/a | 9 |
| May ’24 | US$9.36 | US$12.66 +35.2% | 11.8% | US$15.00 | US$10.00 | n/a | 9 |
| Apr ’24 | US$9.62 | US$13.35 +38.8% | 17.3% | US$18.00 | US$10.00 | US$11.94 | 11 |
| Mar ’24 | US$11.31 | US$13.37 +18.2% | 16.7% | US$18.00 | US$10.00 | US$12.59 | 12 |
| Feb ’24 | US$12.26 | US$13.45 +9.7% | 16.9% | US$18.00 | US$10.00 | US$11.87 | 12 |
| Jan ’24 | US$11.13 | US$13.27 +19.3% | 18.2% | US$18.00 | US$10.00 | US$10.83 | 11 |
| Dec ’23 | US$11.24 | US$13.27 +18.1% | 18.2% | US$18.00 | US$10.00 | US$9.37 | 11 |
| Nov ’23 | US$10.25 | US$12.55 +22.4% | 22.4% | US$18.00 | US$9.00 | US$8.92 | 11 |
| Oct ’23 | US$8.52 | US$13.50 +58.5% | 27.2% | US$21.00 | US$9.00 | US$9.86 | 10 |
| Sep ’23 | US$9.57 | US$13.70 +43.2% | 26.9% | US$21.00 | US$9.00 | US$10.79 | 10 |
| Aug ’23 | US$9.66 | US$13.90 +43.9% | 28.7% | US$21.00 | US$9.00 | US$10.22 | 10 |
| Jul ’23 | US$10.71 | US$14.00 +30.7% | 28.4% | US$21.00 | US$9.00 | US$9.98 | 10 |
| Jun ’23 | US$12.07 | US$14.46 +19.8% | 24.7% | US$21.00 | US$10.00 | US$9.18 | 12 |
| May ’23 | US$10.33 | US$14.38 +39.2% | 25.4% | US$21.00 | US$10.00 | US$9.36 | 12 |
| Apr ’23 | US$10.82 | US$14.12 +30.5% | 25.7% | US$21.00 | US$10.00 | US$9.62 | 13 |
Analysten-Prognose: Das Kursziel liegt weniger als 20% über dem aktuellen Aktienkurs.